Alnylam Pharmaceuticals | ALNY - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
Acadia Pharmaceuticals USD 279.64M 36.37M 2026-06
Agios Pharmaceuticals USD 19.43M 1.34M 2026-03
Alnylam Pharmaceuticals USD 992.69M 167.68M 2026-06
Amgen USD 5.87B 1.02B 2026-03
Arrowhead Research USD 75.25M 1.52M 2026-06
BioCryst Pharmaceuticals USD 214.41M 61.36M 2026-06
BioMarin Pharmaceutical USD 713.42M 142.21M 2026-06
Incyte USD 1.57B 400.89M 2026-06
Ionis Pharmaceuticals USD 265M 22M 2026-06
Moderna USD -566M 792M 2026-03
Neurocrine Biosciences USD 800.7M 12.8M 2026-03
Novartis USD 10.07B 758M 2026-03
PTC Therapeutics USD 232.94M 84.56M 2026-03
Regeneron Pharmaceuticals USD 3.71B 778.2M 2026-06
Sangamo BioSciences -2.39M 1.09M 2024-06
Sanofi EUR 8.11B 343M 2026-03
Sarepta Therapeutics USD 251.15M 370.2M 2026-06
Takeda JPY 813.22B 124.39B 2026-06
Tectonic Therapeutic USD 0 0 2025-03
Ultragenyx Pharmaceutical USD 180M 74M 2026-06
Vertex Pharmaceuticals USD 2.84B 242.4M 2026-06
Xencor USD 51.22M 46.7M 2026-06